Report Summary
The report "2007 Russian Pharma Sector Analysis" provides an extensive research and objective analysis on the growing demand of pharmaceuticals in Russia and presents a clear picture of the country's healthcare and pharmaceutical market.
The Russian pharmaceutical market, in 2006, witnessed one of the strongest growths globally with both the state and commercial segments registering double-digit growth in their sales value. The major impetus for growth was given by the Government's Drug reimbursement programmed, which saw the consumption value of drugs increased by nearly 74% in 2006.
The commercial drugs market, driven by factors such as an ageing population, an increasing demand for imported and expensive medicines, an obligatory health insurance system and increasing disposable incomes, accounts for nearly half of the total pharmaceutical market. Unlike ethical drugs, the nutrition supplements market is dominated by domestic players but the recent restrictions imposed by the State Dumas on the promotion of nutritional supplements have retorted the segment's growth.
The report does a comprehensive analysis of the Russian market, encompassing its demographics, structure of health care sector, size of pharma market, and comparative analysis of the market, among others. Also, a brief overview of the major players operating in the market has been given to present the competitive landscape of the market.
Key Findings
- The DLO programme, that was one of the main drivers fuelling strong growth, may act as a restraint, owing to the government's recent cost cutting measures.
- The Russian pharmaceutical market witnessed a trend where the drugs sales decreased in volume terms but increased in value terms.
- There was a growth in the demand for imported drugs in Russia.
- Russians are now turning towards expensive drugs with a higher efficacy as compared to the cheaper traditional drugs.
Key Issues Analyzed
- Where does the Russian pharmaceutical market stand in comparison to other key global markets?
- What is the market size of various segments in the Russian pharmaceutical industry?
- What is the proportion of domestic and imported drugs in each segment?
- What are the opportunities that will emerge in future for the market?
Research Methodology Used
Information Sources: The information in the report has been taken from various credible sources like books, newspapers, trade journals, and white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to more than 3000 paid databases.
Analysis Methods: The analysis methods include ratio analysis, historical trend analysis, linear regression analysis using software tools, judgmental forecasting and cause and effect analysis.
For the purpose of this report, the Russian pharmaceutical market has been considered to consist of the following segments:
- The commercial drugs market;
- The state segment (DLO programme and hospital segment); and
- The Para pharmaceutical segment (Food Supplements and Cosmetics).
The following currency conversion has been taken in the report:
1 Russian Ruble = US$ 0.039, 1 Euro = US$ 1.38
Report Outline
Chapter 1 Analyst View
Chapter 2 Global Pharmaceutical Market
2.1 Market Size & Growth
2.2 Geographical Performance
2.3 Leading Therapy Classes
2.4 Leading Pharmaceutical Companies
2.5 Leading Drugs
Chapter 3 Russian Demographics & Healthcare Profile
3.1 Population
3.1.1 Life Expectancy
3.1.2 Age Breakup
3.2 Healthcare Structure
3.2.1 Hospital Beds & Doctors
3.2.2 Healthcare Expenditure
Chapter 4 Russian Pharmaceutical Market
4.1 Market Overview
4.1.1 Market Size & Growth
4.1.2 Comparative Analysis
4.2 Commercial Drug Market
4.2.1 Trends
4.2.2 Imported & Domestic Drugs
4.2.3 RX & OTC Drugs
4.2.4 Sales Structure - By ATC Groups
4.2.5 Leading Pharmaceutical Companies
4.2.6 Leading Drugs
4.2.7 Price Analysis
4.3 State Segment of Pharmaceutical Market
4.3.1 DLO Reimbursement Programme
4.3.1.1 Imported & Domestic Drugs
4.3.1.2 RX & OTC Drugs
4.3.1.3 Sales Structure - By ATC Groups
4.3.1.4 Leading Pharmaceutical Companies
4.3.1.5 Leading Drugs
4.3.2 Hospital Segment
4.3.2.1 Imported & Domestic Drugs
4.3.2.2 Drugs Demand - By Price
4.3.2.3 Leading Pharmaceutical Companies
4.3.2.4 Leading Drugs
4.4 Parapharmaceutical Commercial Market
4.4.1 Nutritional Supplements Market
4.4.1.1 Imported & Domestic Nutritional Supplements
4.4.1.2 Leading Nutritional Supplements
4.4.1.3 Nutritional Supplements Demand - By Price
Chapter 5 Industry Analysis
5.1 Drivers
5.1.1 Ageing Population
5.1.2 Increasing Volume & Sales of Expensive Drugs
5.1.3 Government Support & Funding
5.1.4 Medical Insurance
5.1.5 Increasing Disposable Income
5.2 Opportunities
5.2.1 Cardiovascular Drugs
5.2.2 HIV Drugs
5.2.3 High Insulin Demand
5.2.4 Cancer Drugs
5.2.5 Foreign Players
5.2.6 Generics
5.2.7 Clinical Trials Market
5.3 Challenges
5.3.1 Declining Population
5.3.2 DLO Crisis
5.3.3 Ineffective Quality Control of Medicines
5.3.4 Drugs Counterfeiting & Weak IPR Protection
Chapter 6 Future Outlook, 2007- 2011
Chapter 7 Key Players
7.1 Sanofi-Aventis
7.2 Novartis
7.3 Roche Group
7.4 Pfizer Inc
7.5 AstraZeneca
Figures
Figure 2-1: Global-Pharmaceutical Market (in Billion US$), 2001-2006
Figure 2-2: Global-Pharmaceutical Market Growth (%), 2002-2006
Figure 2-3: Global-Pharmaceutical Market by Region (%), 2006
Figure 2-4: Global-Leading Pharmaceutical Companies by Sales, Profit before Taxes & Market Capitalization (in Billion US$), 2006
Figure 3-1: Russia-Population (in Million), 2001-2006
Figure 3-2: Russia-Life Expectancy of Male & Female (in Years), 2001-2006E
Figure 3-3: Russia-Population Breakup by Age (%), 2001-2006
Figure 3-4: Russia-Number of Doctors (per ‘000 Population), 2001-2006E
Figure 3-5: Russia-Number of Hospital Beds (per ‘000 Population), 2001-2006E
Figure 3-6: Russia-Share of Healthcare Expenditure in GDP (%), 2000-2005E
Figure 3-7: Russia-Per Capita Healthcare Expenditure* (in US$), 2000-2005E
Figure 4-1: Russia-Pharmaceutical Market (in Million US$), 2005 & 2006
Figure 4-2: Russia-Share of Key Segments in Pharmaceutical Market (%), 2005 & 2006
Figure 4-3: Global-Top Pharmaceutical Markets Retail Sales (in Billion US$), 2006
Figure 4-4: Global-Top Pharmaceutical Markets Growth in Retail Sales (%), 2006
Figure 4-5: Global-Top Pharmaceutical Markets Per Capita Drug Consumption (in US$), 2006
Figure 4-6: Russia-Share of Personal & State Financing in Pharmaceutical Market (%), 2004-2006
Figure 4-7: Global-Share of State & Personal Financing in Top Pharmaceutical Markets (%), 2006
Figure 4-8: Russia-Commercial Drug Market (in Million US$), 2005 & 2006
Figure 4-9: Russia-Trends in Commercial Drugs Market (%), 2006
Figure 4-10: Russia-Share of Imported & Domestic Drugs in Commercial Drugs Market by Sales Value (%), 2005 & 2006
Figure 4-11: Russia-Share of Imported & Domestic Drugs in Commercial Drugs Market by Sales Volume (%), 2005 & 2006
Figure 4-12: Russia-Share of RX & OTC Drugs in Commercial Drugs Market by Sales Value (%), 2005 & 2006
Figure 4-13: Russia-Share of RX & OTC Drugs in Commercial Drugs Market by Sales Volume (%), 2005 & 2006
Figure 4-14: Russia-Growth of Major ATC Groups in Commercial Drugs Market (%), 2006
Figure 4-15: Russia-Price Index for Drugs in Commercial Drugs Market (%), 2005 & 2006
Figure 4-16: Russia-Price Index for Imported & Domestic Drugs in Commercial Drugs Market (%), 2005 & 2006
Figure 4-17: Russia-Consumer Price Index (%), 2006
Figure 4-18: Russia-State Segment of Pharmaceutical Market (in Million US$), 2005 & 2006
Figure 4-19: Russia-Consumption Value of DLO Programme (in Billion US$), 2005 & 2006
Figure 4-20: Russia-Share of Imported & Domestic Drugs in the DLO List of Full & Trade Name (%), 2006
Figure 4-21: Russia-Share of Imported & Domestic Drugs Sales under DLO Programme (%), 2005 & 2006
Figure 4-22: Russia-Share of RX & OTC Drugs Sales Value under DLO Programme (%), 2005 & 2006
Figure 4-23: Russia-Share of RX & OTC Drugs Sales Volume under DLO Programme (%), 2005 & 2006
Figure 4-24: Russia-Share of ATC Groups Sales under DLO Programme (%), 2005 & 2006
Figure 4-25: Russia-Share of Imported & Domestic Drugs Sales Value under Hospital Segment (%), 2005 & 2006
Figure 4-26: Russia-Share of Imported & Domestic Drugs Sales Volume under Hospital Segment (%), 2005 & 2006
Figure 4-27: Russia-Drugs Demand by Price under Hospital Segment (%), 2005 &2006
Figure 4-28: Russia-Parapharmaceutical Market (in Million US$), 2005 & 2006
Figure 4-29: Russia-Nutritional Supplements Market (in Million US$), 2005 & 2006
Figure 4-30: Russia-Nutritional Supplements Market Volume (in Million Units), 2005 & 2006
Figure 4-31: Russia-Share of Imported & Domestic Nutritional Supplements Sales Value & Volume (%), 2006
Figure 4-32: Russia-Imported Nutritional Supplements Breakup by Country (%), 2006
Figure 4-33: Russia-Imported & Domestic Nutritional Supplements Demand by Price (%), 2006
Figure 5-1: Russia-Percentage of Population above 65 Years of Age, 2001-2006
Figure 5-2: Russia-Pharmaceutical Market Growth by Segment (%), 2006
Figure 5-3: Russia-Personal Disposable Income (in Billion US$), 2001-2006E
Figure 5-4: Russia-Deaths from Cardiovascular Diseases in Total Deaths (%), 2005 & 2030F
Figure 5-5: Russia-Number of HIV Patients (in '000), 2003 & 2005E
Figure 5-6: Russia-HIV Drugs Import (in Million US$), 2004 & 2005E
Figure 5-7: Russia-Forecast for Number of Diagnosed Diabetes Patients (in '000), 2003 & 2025F
Figure 5-8: Russia-Insulin Market (in Million US$), 2006E-2008
Figure 5-9: Russia-Deaths from Cancer in Total Deaths (%), 2005 & 2030F
Figure 5-10: Russia-Generic Drugs Market (in Billion Euro), 2006 & 2010F
Figure 5-11: Russia-Number of Approved Clinical Trials, 2001-2006
Figure 5-12: Russia-Number of Patients Participating in Clinical Trials, 2002 & 2006
Figure 5-13: Russia-Forecast for Population (in Million), 2007-2011
Figure 6-1: Russia-Forecast for Pharmaceutical Market (in Million US$), 2007-2011
Tables
Table 2-1: Global-Pharmaceutical Market by Region (in Billion US$), 2006
Table 2-2: Global-Leading Therapy Classes by Sales (in Billion US$), 2006
Table 2-3: Global-Leading Drugs by Sales (in Billion US$), 2006
Table 4-1: Russia-Leading Pharmaceutical Companies by Sales (in Million US$), 2005 & 2006
Table 4-2: Russia-Sales Structure of ATC Groups in Commercial Drugs Market, 2006
Table 4-3: Russia-Leading Pharmaceutical Companies in Commercial Drugs Market by Sales (in Million US$), 2005 & 2006
Table 4-4: Russia-Leading Drugs in Commercial Drugs Market by Sales (in Million US$), 2005 & 2006
Table 4-5: Russia-Sales Structure of ATC Groups under DLO Programme, 2006
Table 4-6: Russia-Leading Pharmaceutical Companies under DLO Programme by Sales (in Million US$), 2005 & 2006
Table 4-7: Russia-Leading Drugs under DLO Programme by Sales (in Million US$), 2005 & 2006
Table 4-8: Russia-Leading Pharmaceutical Companies under Hospital Segment by Sales (in Million US$), 2005 & 2006
Table 4-9: Russia-Leading Drugs under Hospital Segment by Sales (in Million US$), 2005 & 2006
Table 4-10: Russia-Leading Nutritional Supplements in Pharmaceutical Market by Sales (in Million US$), 2005 & 2006
Table 7-1: Sanofi-Aventis-Key Financials (in Million US$), 2004-2006
Table 7-2: Novartis-Key Financials (in Million US$), 2004-2006
Table 7-3: Roche Group-Key Financials (in Million CHF), 2004-2006
Table 7-4: Pfizer Inc-Key Financials (in Million US$), 2004-2006
Table 7-5: AstraZeneca-Key Financials (in Million US$), 2004-2006
